Larvol Delta - Citius-Receives-FDA-Response-on-PreInvestigational-New-Drug-PIND-Application-for-its-Induced-Mesenchymal-Stem-Cells-iMSCs-to-Treat-Acute-Respiratory-Distress-Syndrome-ARDS-in-Patients-with-COVID19

mesenchymal stem cell therapy - Novellus, Citius

https://www.prnewswire.com/news-releases/citius-receives-fda-response-on-pre-investigational-new-drug-pind-application-for-its-induced-mesenchymal-stem-cells-imscs-to-treat-acute-respiratory-distress-syndrome-ards-in-patients-with-covid-19-301084325.html

Jun 26, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next